Treatment of ophthalmic conditions by selectively removing senescent cells from the eye
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
1. A method of treating an ophthalmic disease or disorder in a subject, comprising:
administering in or around an eye of a subject in need thereof a pharmaceutical composition that contains an effective amount of a small-molecule means for selectively inhibiting Bcl-2 or Bcl-xL,
thereby killing senescent cells in the eye that are causing symptoms of the ophthalmic disease or disorder in the subject,
wherein the senescent cells are defined as non-cancerous cells that express p16,
the pharmaceutical composition is administered intraocularly or intravitreally, and
the pharmaceutical composition is administered in a therapeutically effective course of therapy that includes a period of treatment followed by a non-treatment interval of at least two weeks.
2. The method of claim 1 , wherein the ophthalmic disease or disorder is presbyopia.
3. The method of claim 1 , wherein the ophthalmic disease or disorder is macular degeneration.
4. The method of claim 1 , wherein the ophthalmic disease or disorder is the dry form of age-related macular degeneration.
5. The method of claim 1 , wherein the ophthalmic disease or disorder is the wet form of age-related macular degeneration.
6. The method of claim 1 , wherein the ophthalmic disease or disorder is glaucoma.
7. The method of claim 1 , wherein the pharmaceutical composition is a sustained-release formulation.
8. The method of claim 1 , wherein the pharmaceutical composition delays disorganization of type IV collagen in the eye.
9. The method of claim 1 , wherein the means for selectively inhibiting Bcl-2 or Bcl-xL is selected from WEHI-539, A-1155463, ABT-737, ABT-199, Obatoclax, BXI-61, BXI-72, 2,3-DCPE, ((R)-4-(4-chlorophenyl)-3-(3-(4-(4-(4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenylsulfonamido)phenyl) piperazin-1-yl)phenyl)-5-ethyl-1-methyl-1H-pyrrole-2-carboxylic acid (“Compound 21”), (R)-5-(4-chlorophenyl)-4-(3-(4-(4-(4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitro phenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-1-ethyl-2-methyl-1H-pyrrole-3-carboxylic acid (“Compound 14”), (R)-5-(4-chlorophenyl)-4-(3-(4-(4-(4-(4-(dimethylamino)-1-(phenylthio) butan-2-ylamino)-3-nitrophenylsulfonamido)phenyl)piperazin-1-yl)phenyl)-1-isopropyl-2-methyl-1H-pyrrole-3-carboxylic acid (“Compound 15”), BM-957, BM-1074, and BM-1197.
10. The method of claim 1 , wherein the means for selectively inhibiting Bcl-2 or Bcl-xL is ABT-263 (Navitoclax).
11. The method of claim 1 , wherein a single dose of the pharmaceutical composition is administered during the period of treatment.